Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alglucosidase alfa biomarker and muscle biopsy study in late-onset Pompe disease
NL-OMON39502Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2012
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoint: Percent reduction from baseline in tissue glycogen content in muscle biopsy samples at Week 26. Started Jan 2012; status: active, not recruiting.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON39502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39502.